Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8SCON)

Drug Name

AZD5904 Drug Info

Synonyms

AZD5904; UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 1	[1]
Multiple sclerosis	8A40	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 10264211
CAS Number: CAS 618913-30-7
TTD Drug ID: DM8SCON

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myeloperoxidase (MPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-101	DMM1YC4	Infectious disease	1A00-CA43.1	Phase 3	[3]
Mitiperstat	DM0BL2G	Heart failure with preserved ejection fraction	BD11.0	Phase 2/3	[4]
AZD-3241	DMANC59	Parkinson disease	8A00.0	Phase 2	[5]
AZD4831	DMRP3N8	Heart failure	BD10-BD13	Phase 1	[6]
INV-311	DM8BZVI	Inflammation	1A00-CA43.1	Investigative	[7]
4-aminobenzoic acid hydrazide	DMP2GN7	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloperoxidase (MPO)	TTVCZPI	PERM_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7728).
2	Clinical pipeline report, company report or official report of AstraZeneca (2009).
3	In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42.
4	Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496.
5	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789).
8	Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010 Nov;335(2):389-400.